Natco Pharma Receives USFDA Tentative Approval for Generic Olaparib Tablets
Natco Pharma received tentative approval from the U.S. Food and Drug Administration for its generic Olaparib tablets in 100 mg and 150 mg strengths, bioequivalent to AstraZeneca's Lynparza. Under a partnership, Natco will manufacture the drug while Alembic Pharmaceuticals will distribute it in the U.S. Olaparib is used to treat certain ovarian, breast, pancreatic, and prostate cancers. The product faces ongoing Paragraph IV patent litigation. Olaparib's U.S. sales were estimated at around $1.4 billion for the year ending March 2026.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 46/100.
Outlets measured: thehindu, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 20 Jul, 11:25 am. Other outlets followed.